Alterity Therapeutics Lim... (ATHE)
El precio, las cifras principales y las últimas noticias, en un solo sitio.
Alterity Therapeutics Limited (ATHE): cotización, análisis y datos
No hay datos disponibles
| Precio de compra | n/a |
| Capitalización de mercado | n/a |
| Ingresos (TTM) | 6.64M |
| Beneficio neto (TTM) | -14.59M |
| -0.04 | |
| n/a | |
| n/a | |
| -5.13 | |
| P/B (TTM) | 0.04 |
| P/S (TTM) | 12.48 |
| Fecha de resultados | Feb 26, 2013 |
| Precio de venta | n/a |
| Volumen | NaN |
| Volumen medio (20D) | n/a |
| Abierto | n/a |
| Anterior Cerrar | n/a |
| Rango del día | n/a - n/a |
| Rango de 52 semanas | n/a - n/a |
| analista | n/a |
| Precio objetivo | n/a |
| Dividendos | n/a |
| Fecha ex dividendo | n/a |
Acerca de ATHE
Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy ea...
Desempeño financiero
En 2025, los ingresos de Alterity Therapeutics fueron 0, un aumento de undefined% en comparación con 0 del año anterior. Las ganancias fueron -12.15M, una disminución de -36.48%.
Estados financierosLos analistas proyectan ingresos de ... Actualizar
11 meses hace · Insider Monkey
Alterity Therapeutics (ATHE) Presents Positive Phase 2 Data for ATH434Alterity Therapeutics Limited (NASDAQ:ATHE) is one of the best performing ASX stocks in 2025. On September 15, the company shared data from its Phase 2 clinical trial of the drug ATH434-201 at the Ame...